How Multiple Myeloma Causes Congestive Heart Failure
Multiple myeloma causes CHF through several distinct mechanisms: high-output heart failure from extensive bone disease creating arteriovenous shunts (most characteristic), cardiac amyloidosis from light chain deposition, direct myocardial infiltration by immunoglobulin deposits, and cardiotoxicity from myeloma treatments.
Primary Disease-Related Mechanisms
High-Output Heart Failure (Most Characteristic)
The most distinctive mechanism is high-output heart failure, occurring in approximately 23.5% of MM patients 1. Extensive lytic bone lesions create innumerable intramedullary arteriovenous fistulas that dramatically increase cardiac output 2, 3. This mechanism is strongly associated with severe bone involvement—all patients with high cardiac output states in one study had extensive bone disease compared to only 35% without high output 1.
Key features of this presentation:
- Cardiac index ≥4.0 L/min/m² (often 10-15 L/min) 2, 1
- Diuretics are ineffective because the problem is excessive flow, not volume retention 2
- Elevated filling pressures despite high output 2
- Can rapidly progress to respiratory failure requiring mechanical ventilation 2
Cardiac Amyloidosis
Light chain amyloidosis causes restrictive cardiomyopathy through:
- Myocardial infiltration by amyloid fibrils 4
- Lysosomal dysfunction and ROS accumulation 4
- Severe diastolic dysfunction of both ventricles 5, 6
Direct Myocardial Infiltration
Non-amyloid immunoglobulin deposition disease can cause:
- Diastolic heart failure from intercellular fibrillar tissue infiltration 5
- This occurs without amyloid and represents a distinct pathologic entity 5
Additional Contributing Mechanisms
Enhanced Angiogenesis and Metabolic Alterations
MM creates a pro-angiogenic environment through 3:
- Increased vascular endothelial growth factor (VEGF) production
- Glutaminolysis and hyperammonemia affecting cardiac metabolism
- Hemorheological alterations with increased plasma viscosity
Anemia-Related High Output
Severe anemia from marrow replacement independently contributes to high-output physiology 6.
Treatment-Related Heart Failure
Proteasome Inhibitors
Carfilzomib carries the highest cardiac risk (OR 2.68) 7, 8, causing:
- Cardiac failure and congestive heart failure
- Atrial fibrillation
- QT prolongation (especially with dexamethasone) 8
Bortezomib has moderate risk (OR 1.67-2.68) for cardiac failure and atrial fibrillation 7, 8.
Ixazomib shows no significant CAE safety signals 8.
Immunomodulatory Drugs
Lenalidomide and thalidomide carry an OR of approximately 2 for high-grade cardiac toxicity 7.
Anthracyclines
Doxorubicin causes cardiotoxicity via topoisomerase IIβ inhibition 4.
Clinical Implications
Common pitfall: Treating MM-related high-output heart failure with aggressive diuresis is futile and potentially harmful 2. The cardiac output must be reduced by treating the underlying myeloma.
Effective treatment approach for high-output failure: Anti-angiogenic agents (lenalidomide or thalidomide) combined with dexamethasone produce rapid improvement—patients can achieve brisk diuresis within 48 hours and normalize cardiac output within days to weeks 2. This represents "pharmacologic fistula ligation" by reducing the arteriovenous shunting 2.
Mortality impact: High-output heart failure in MM carries significant mortality risk, with deaths reported in case series 2. Post-discharge cardiovascular events (occurring at median 13 months) predict worse survival, while in-hospital events are typically reversible 9.
Surveillance strategy: Cardiovascular events affect approximately 7.5% of MM patients overall 7, but this varies substantially by treatment regimen and patient characteristics. The 2025 EHA-EMN guidelines emphasize managing cardiovascular complications as part of comprehensive MM care 10.